

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### Abaloparatide for treating osteoporosis in postmenopausal women [ID882]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The following equalities issues were raised during consultation

- The importance of ensuring that transgender patients are afforded the full benefits as demonstrated by clinical trials for abaloparatide independent of gender assigned at birth
- Men and women should both be considered
- Relying on a BMD defined diagnosis risks excluding people who are unable to have a scan due to local availability, or mobility issues or have unreliable BMD readings due to surgery or osteoarthritis for example
- People with cognitive or physical disability who have problems with administration or those with an aversion to injections, will need consideration and support if this treatment is recommended and prescribed.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

- Specifically regarding men and women being considered, NICE can only appraise a technology within its marketing authorisation. The marketing authorisation for abaloparatide explicitly states "post

menopausal women". Therefore any recommendation will be in line with the marketing authorisation.

- The committee will consider carefully if its recommendations makes access to abaloparatide more difficult for certain groups.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

**Approved by Associate Director (name):** .....Richard Diaz.....

**Date:** 12 July 2023